References
- Reddel HK, Hurd SS, FitzGerald JM. World Asthma Day. GINA 2014: a global asthma strategy for a global problem. Int J Tuberc Lung Dis 2014;18:505-6. https://doi.org/10.5588/ijtld.14.0246
- Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012;11:958-72. https://doi.org/10.1038/nrd3792
- Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther 2013;26:710-5. https://doi.org/10.1016/j.pupt.2013.07.003
- Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res 2017;18:129. https://doi.org/10.1186/s12931-017-0614-x
- Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160:93-101. https://doi.org/10.1159/000338998
- Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223. https://doi.org/10.1016/S0140-6736(12)61689-4
- Lai CK, Kim YY, Kuo SH, Spencer M, Williams AE. Cost of asthma in the Asia-Pacific region. Eur Respir Rev 2006;15:10-6. https://doi.org/10.1183/09059180.06.00009802
- Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24. https://doi.org/10.1186/1471-2466-9-24
- Alam R, Good J, Rollins D, Verma M, Chu H, Pham TH, et al. Airway and serum biochemical correlates of refractory neutrophilic asthma. J Allergy Clin Immunol 2017;140:1004-14.e13. https://doi.org/10.1016/j.jaci.2016.12.963
- Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9. https://doi.org/10.1136/thorax.57.10.875
- Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015;16:45-56.
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25. https://doi.org/10.1038/nm.2678
- Ito K, Herbert C, Siegle JS, Vuppusetty C, Hansbro N, Thomas PS, et al. Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. Am J Respir Cell Mol Biol 2008;39:543-50. https://doi.org/10.1165/rcmb.2008-0028OC
- Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615. https://doi.org/10.1128/CMR.00078-09
- Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008;117:393-405. https://doi.org/10.1016/j.pharmthera.2007.11.001
- Wong EH, Porter JD, Edwards MR, Johnston SL. The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med 2014;2:657-70. https://doi.org/10.1016/S2213-2600(14)70107-9
- Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55. https://doi.org/10.1164/rccm.200707-1134OC
- Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9. https://doi.org/10.1136/thoraxjnl-2012-202698
- Bergquist M, Jonasson S, Hjoberg J, Hedenstierna G, Hanrieder J. Comprehensive multiplexed protein quantitation delineates eosinophilic and neutrophilic experimental asthma. BMC Pulm Med 2014;14:110. https://doi.org/10.1186/1471-2466-14-110
- Zhang F, Huang G, Hu B, Qian GS, Song Y. Recombinant HMGB1 A box protein inhibits Th17 responses in mice with neutrophilic asthma by suppressing dendritic cell-mediated Th17 polarization. Int Immunopharmacol 2015;24:110-8.
- Zhao Y, Huang Y, He J, Li C, Deng W, Ran X, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma. Immunol Lett 2014;157:9-15.
- Zhao S, Jiang Y, Yang X, Guo D, Wang Y, Wang J, et al. Lipopolysaccharides promote a shift from Th2-derived airway eosinophilic inflammation to Th17-derived neutrophilic inflammation in an ovalbumin-sensitized murine asthma model. J Asthma 2017;54:447-55.
- McGovern TK, Robichaud A, Fereydoonzad L, Schuessler TF, Martin JG. Evaluation of respiratory system mechanics in mice using the forced oscillation technique. J Vis Exp 2013;(75):e50172.
- Shalaby KH, Gold LG, Schuessler TF, Martin JG, Robichaud A. Combined forced oscillation and forced expiration measurements in mice for the assessment of airway hyperresponsiveness. Respir Res 2010;11:82. https://doi.org/10.1186/1465-9921-11-82
- Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets 2007;11:745-55. https://doi.org/10.1517/14728222.11.6.745
- Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156(3 Pt 1):737-43. https://doi.org/10.1164/ajrccm.156.3.9610046
- Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160(5 Pt 1):1532-9. https://doi.org/10.1164/ajrccm.160.5.9806170
- Annunziato F, Romagnani S. Mouse T helper 17 phenotype: not so different than in man after all. Cytokine 2011;56:112-5. https://doi.org/10.1016/j.cyto.2011.06.009
- Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013;42:239-51. https://doi.org/10.1183/09031936.00136712
- Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138:1202-12. https://doi.org/10.1378/chest.10-0196
- Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM. Inflammasomes in COPD and neutrophilic asthma. Thorax 2015;70:1199-201. https://doi.org/10.1136/thoraxjnl-2014-206736
- Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131:636-45. https://doi.org/10.1016/j.jaci.2012.12.1564
- Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013;169:1024-34. https://doi.org/10.1111/bph.12187
Cited by
- Effects of Particulate Matter 10 Inhalation on Lung Tissue RNA expression in a Murine Model vol.84, pp.1, 2021, https://doi.org/10.4046/trd.2020.0107
- Tiotropium Bromide Has a More Potent Effect Than Corticosteroid in the Acute Neutrophilic Asthma Mouse Model vol.85, pp.1, 2018, https://doi.org/10.4046/trd.2021.0118